Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sattva Medicine Psychiatry/Psychotherapy Practice, Miami, FL, USA.
Sci Rep. 2024 Nov 14;14(1):28022. doi: 10.1038/s41598-024-78736-1.
Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression was used to identify predictors of openness to clinical use. Most participants (71.2%) were female and White (85.8%), with a mean (SD) age of 45.5 (12.7) years. Registered nurses (25.4%) and physicians (17.7%) comprised the largest professional groups. Respondents endorsed strong belief in therapeutic promise, and moderate openness to clinical use and support for legal access to both substances, with higher overall ratings for psilocybin compared to MDMA. Objective knowledge items revealed low knowledge of therapeutic uses, risks, and pharmacology. Primary concerns were lack of trained providers, financial cost, and potential contraindications. Prior psychedelic use, self-rated knowledge, younger age, and professional role predicted openness to clinical use of psilocybin and MDMA, with physicians reporting lower openness. As psychedelics continue to garner popular and scientific interest, results indicate a pressing need for additional formal training to provide balanced, evidence-based information from trusted sources.
迷幻辅助疗法（PAT）使用迷幻蘑菇和 MDMA 等物质，已显示出对抑郁症和创伤后应激障碍等疾病的治疗潜力。迷幻蘑菇和 MDMA 可能在未来十年内成为批准的药物。本研究通过匿名在线调查评估了 879 名美国医疗保健专业人员对 PAT 的知识和态度。使用多变量线性回归来确定对临床应用开放程度的预测因素。大多数参与者（71.2%）为女性和白人（85.8%），平均（SD）年龄为 45.5（12.7）岁。注册护士（25.4%）和医生（17.7%）构成了最大的专业群体。受访者强烈相信治疗潜力，并对临床应用和支持这两种物质的合法获取表示适度开放，与 MDMA 相比，对迷幻蘑菇的总体评价更高。客观知识项目显示出对治疗用途、风险和药理学的知识不足。主要关注的问题是缺乏经过培训的提供者、财务成本和潜在的禁忌症。先前使用迷幻剂、自我评估的知识、年龄较小和专业角色预测了对迷幻蘑菇和 MDMA 的临床应用的开放程度，医生报告的开放性较低。随着迷幻剂继续引起公众和科学界的兴趣，结果表明迫切需要额外的正式培训，以提供来自可靠来源的平衡、基于证据的信息。
